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Abstract 
Purpose: Triple negative breast cancer (TNBC) is a distinct subtype of breast cancer with unique pathologic, 
molecular and clinical behavior. It occurs more frequently in young blacks and has been reported to have a shorter 
disease-free interval. We undertook this study to analyze the demographic characteristics, failure patterns, and survival 
outcomes in this disease.
Methods: A total of 448 non-Hispanic black and white women were identified over a 15 year period from 1996 to 
2011. Demographic and clinical information including age, race, menopausal status, stage, tumor characteristics, and 
treatments were collected. Fisher’s exact test and multivariable Cox regression were used to compare failure patterns 
and survival outcomes between races.
Results: 49 % (n = 223) were black. 59 % patients were between 41 and 60 years, with 18 % ≤40 years. 57 % were 
premenopausal and 89 % had grade 3 tumors. Stage II (47 %) was most frequent stage at diagnosis followed by stage 
III (28 %). 32 % had lymphovascular invasion. Adjusting for age, stage, and grade, there was no difference in survival 
outcomes (OS, DFS, LFFS, and DFFS) between the two races. 62 (14 %) patients failed locally either in ipsilateral breast 
or chest wall, and 19 (4 %) failed in the regional lymphatics. Lung (18 %) was the most frequent distant failure site with 
<12 % each failing in brain, liver and bones.
Conclusion: Failure patterns and survival outcomes did not differ by race in this large collection of TNBC cases. 
Lung was the predominate site of distant failure followed by brain, bone, and liver. Few patients failed in the regional 
lymphatics.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Breast cancer is the most common malignancy among 
women in developed countries.
Triple-negative breast cancer (TBNC) is a distinct sub-
type of breast cancer with unique pathological, molecular 
and clinical behavior. Phenotypically, these tumors are 
negative for estrogen-receptor (ER), progesterone-recep-
tor (PR) and human epidermal growth factor receptor 2 
(HER2). TNBC often is used synonymously with basal 
subtype breast cancer, which is one of 5 subtypes based 
on gene expression obtained from microarray data. How-
ever, there exists 20–30 % discordance between these two 
entities (Anders and Carey 2009). TNBC accounts for 
approximately 12–17 % of all breast cancers (Anders and 
Carey 2009; Foulkes et  al. 2010), corresponding to over 
172,000 patients among an estimated 1 million cases of 
breast cancer diagnosed annually worldwide (Anders 
and Carey 2009). Owing to lack of receptor expres-
sion, TNBCs are not candidates for targeted biological 
therapies.
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TNBCs are reported to have an aggressive clinical 
course, worse prognosis, and a shorter disease-free inter-
val and overall survival compared with receptor posi-
tive breast cancers (Anders and Carey 2009; Rhee et  al. 
2008; Tian et  al. 2008; Nishimura and Arima 2008). 
Although these tumors tend to recur earlier than lumi-
nal breast cancers in the first 5  years following diagno-
sis, this aggressiveness appears to diminish beyond this 
timeframe (Dent et al. 2007). The visceral organs and soft 
tissue are common sites of recurrence, with lower rates of 
bone involvement (Liedtke et al. 2008).
Pre-menopausal black women have a higher incidence 
of TNBC than white women, which suggests possible dif-
ferences on a molecular level (Carey et  al. 2006; Bauer 
et al. 2007a; Morris et al. 2007). However, the exact causal 
mechanism is not fully understood. While several studies 
have focused on disparate outcomes for TNBC among 
black women, findings have been inconsistent (National 
Cancer Institute 1990; Bradley et al. 2002; Ayanian et al. 
1993; McWhorter and Mayer 1987; Furberg et  al. 2001; 
Ihemelandu et al. 2007).
We undertook this study to compare failure patterns 
and survival outcomes between non-Hispanic white and 
black women diagnosed with TNBC.
Methods
Patients for this study were collected from two large, ter-
tiary referral centers in the southeastern region of the 
United States. Women with triple negative breast cancer 
(TNBC), defined as negative estrogen, progesterone and 
HER2 receptor status (<1  % of tumor cells demonstrat-
ing positive nuclear staining on immunohistochemis-
try), were identified from the institution tumor registry 
after obtaining the Institutional Review Board approval. 
Between 1996 and 2011, a total of 448 non-Hispanic 
women were identified and are included in this analy-
sis. The medical records of each patient were reviewed 
to extract information. We collected information on 
both demographic and tumor characteristics including 
age, race, menopausal status, insurance type, pathol-
ogy, grade, stage and lymphovascular invasion (LVI). All 
patients were staged based on AJCC—6th edition after 
reviewing both clinical and radiographical information. 
Other pertinent information collected were type of treat-
ments received including surgery, chemotherapy and 
radiation therapy. Surgery included partial mastectomy, 
mastectomy or none. Chemotherapy was categorized by 
neoadjuvant and adjuvant chemotherapy or none. Radia-
tion was categorized as yes or no.
We collected detail information on tumor failure type 
including local, regional and distal. If patients failed in the 
same breast or chest wall, it was referred as local. If the 
recurrence were in ipsilateral axilla, internal mammary 
or supraclavicular region, it was scored as regional. All 
other sites were called distant failure. We also collected 
information on site of distant failure including lungs, 
bones, central nervous system (CNS), liver, non-regional 
lymph nodes and others.
Statistical analysis
Fisher’s exact test was used to compare frequencies for 
categorical variables. The Kaplan–Meier product-limit 
method was used to determine overall (OS), disease-free 
(DFS), local failure-free (LFFS), and distant failure-free 
(DFFS) survival probabilities, with p-values for group 
comparisons based on the log-rank statistic. Adjusted 
hazard ratios (aHR) and 95  % confidence intervals (CI), 
were computed using a Cox regression model. Multivari-
able models were adjusted for age, stage, and grade. Based 
on the test statistic of Grambsch and Therneau, the par-
allel (proportional) hazards assumption was not violated 
in our models. An iterative expectation–maximization 
procedure was used to account for missing values (impu-
tation efficiency >99 %). Rounding was performed using 
the method of Holly and Whittemore. Statistical signif-
icance was defined as p ≤  0.05. SAS, version 9.4 (Cary, 
NC) was used for all analyses.
Results
Patient and tumor characteristics
Patients were roughly equally distributed between races, 
with 49  % black (n  =  218) and 51  % white (n  =  230) 
(Table 1). More than half (59 %) of patients were between 
the ages of 41 and 60. Another 18 % were ≤40 years old, 
and 23 % were ≥61 years old. There was a significant dif-
ference in age distribution between black and white par-
ticipants (p = 0.0006), with a greater proportion of white 
patients being ≥61 years old.
Of the 448 patients, the largest percentage (47  %, 
n  =  212) presented with Stage II disease followed by 
stage III disease with 28 % (n = 125). Only 5 % (n = 24) 
had Stage IV disease at presentation. There was a sig-
nificant difference in stage of disease between black and 
white patients (p =  0.026), with a greater proportion of 
white patients having Stage IV disease.
The majority of patients (89 %, n = 397) had Grade 3 
disease, as expected for TNBC. There was no signifi-
cant difference in distribution of disease grade between 
black and white patients. One hundred forty three (143) 
patients (32 %) had lymphovascular invasion.
Treatment
Almost all patients (93  %) received chemotherapy, with 
46  % receiving neoadjuvant chemotherapy and 46  % 
receiving adjuvant chemotherapy (Table  2). Although 
slightly more black than white patients received 
Page 3 of 7Prasad et al. SpringerPlus  (2016) 5:756 
neoadjuvant chemotherapy (48 vs 45 %), the percentage 
patients with a complete response to neoadjuvant chem-
otherapy was nearly equal between races.
Similarly, 92  % of patients underwent surgery, with 
45  % opting for breast-conserving surgery (BCS) and 
47  % opting for mastectomy. There was a significant 
difference in type of surgery between black and white 
patients, with a greater proportion of black patients hav-
ing BCS (p = 0.0010).
Most patients (73  %, n  =  329) underwent radiation 
therapy. There was a significant difference in utilization of 
radiation between black and white patients (p = 0.0105), 
with a greater proportion of black patients receiving radi-
ation (p = 0.0073).
Patterns of failure
Lung (18 %) was the most common site of distant failure 
followed by brain (12  %), liver (11  %) and bone (11  %) 
(Fig. 1). Approximately 14 % of patients developed local 
breast or chest wall failure and 3 % of women developed 
contralateral breast cancer. In addition, we also observed 
failure involving non-regional lymphatics to be high 
at 13  %. Only 4  % of patients had skin and soft tissue 
involvement outside the breast and chest wall. Regional 
lymph node failure was 4 %. There was no significant dif-
ference in sites of overall failure pattern between black 
and white patients.
Patterns of survival
Follow-up time ranged from 0.14 to 14  years, with the 
average patient being followed for 3.8  years. Small but 
continuous occurrences of failure were observed both 
locally and distally (Fig. 2). Even though there were sig-
nificant differences seen in age, stage and local treatment 
distribution between the two groups, survival end points 
between the two races were similar. For example, the 
5-year OS, DFS, LFFS, and DFFS was 68, 60, 63 and 63 % 
for blacks and 65, 63, 64, and 64  % for whites, respec-
tively. Adjusting for age, stage, and grade, hazard ratio 
CIs for each survival outcome included unity (Figs. 3a, b 
and 4a, b). The additional adjustment for year period of 
diagnosis (≤2000, 2001–2005, ≥2006) or insurance type 
did not substantively change our findings.
Table 1 Patient and  tumor characteristics comparison 
between black and white women
† Fisher’s exact test
a Non-Hispanic
Characteristic % (n) Black  % (n) White  % (n) p value†
Racea 100 (448)
 Black 49 (218)
 White 51 (230)
Age (years)
 ≤40 18 (79) 17 (36) 19 (43) 0.0004
 41–60 59 (264) 67 (147) 51 (117)
 ≥61 23 (105) 16 (35) 30 (70)
Stage
 I 19 (87) 16 (35) 23 (52) 0.026
 II 47 (212) 53 (116) 42 (96)
 III 28 (125) 28 (60) 28 (66)
 IV 5 (24) 3 (7) 7 (17)
Grade (differentiation)
 1 (Well) 1 (6) 1 (2) 2 (4) 0.79
 2 (Moderately) 10 (45) 10 (21) 10 (24)
 3 (Poorly) 89 (397) 89 (195) 88 (202)
Table 2 Treatment characteristics comparison between black 
and white women
† Fisher’s exact test
a Lumpectomy
Characteristic % (n) Black  % (n) White  % (n) p value†
Chemotherapy
 Neoadjuvant 46 (208) 48 (105) 45 (103) 0.055
  Complete response 29 (61) 30 (31) 29 (30)
  Partial response 71 (147) 70 (74) 71 (73)
 Adjuvant 46 (208) 48 (104) 45 (104)
 No chemotherapy 7 (32) 4 (9) 10 (23)
Surgery
 Breast-conserving 
surgerya
45 (203) 53 (116) 38 (87) 0.0010
 Mastectomy 47 (211) 38 (83) 56 (128)
 No surgery 8 (34) 9 (19) 7 (15)
Breast radiation
 Radiation 73 (329) 79 (173) 68 (156) 0.0073
 No radiation 27 (119) 21 (45) 32 (74)
Fig. 1 Site failure by race
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Discussion
TNBC accounts for only 10–17  % of all breast cancers, 
yet is responsible for a relatively large proportion of 
breast cancer deaths owing to its inherent aggressive 
biology (Dent et  al. 2007; Podo et  al. 2010). Another 
aggressive subtype is HER2 positive breast cancer. This 
type used to have shorter disease-free survival rates until 
the wide spread availability of HER2 directed therapy uti-
lizing trastazumab with significant improvement in sur-
vival in the modern era. Triple negative subtype on the 
other hand lacks any specific target and currently is sub-
ject to vigorous investigations to improve its outcome. 
TNBC also is a biologically extremely heterogeneous 
group of breast cancer, with a high likelihood of recur-
rence during the first 2–3 years after diagnosis (Foulkes 
et  al. 2010). Dent et  al. (2007) found that patients with 
TNBC subtype had more likelihood of distant recur-
rence and death from breast cancer within 5  years of 
diagnosis. They also noted that distant recurrence and 
breast cancer mortality was seen in the first 5–7  years 
with peak time at 3 years but not after that time period. 
Liedtke et al. (2008) also reported similar findings. They 
evaluated response to neoadjuvant chemotherapy among 
more than 1000 patients from 1985 to 2004 and reported 
3 year progression-free survival and OS rates for TNBC 
were poorer compared with other subtypes. They also 
reported that death rates were higher only in the first 
3 years of diagnosis reaching a plateau after that period. 
In our study we noted a similar significant drop in OS 
and DFS in the first 5  years. In addition, we also noted 
a small but persistent increase in death and recurrence 
occurring beyond 5 years. This is in contrast with the two 
previously reported series.
There are conflicting reports about local or loco-
regional recurrence rates (LRR) in TNBC following 
either breast conserving therapy (BCT) or mastectomy. 
While some reports showed very low incidence of LRR 
in TNBC of 3–8 % (Freedman et al. 2009; Nguyen et al. 
2008; Solin et  al. 2009), other series have shown this to 
be in the range of 10–20  % (Dent et  al. 2007; Abdulka-
rim et al. 2011; Haffty et al. 2006; Voduc et al. 2010). In 
addition, while several of these reports (Dent et al. 2007; 
Freedman et al. 2009; Haffty et al. 2006) did not find any 
difference in LRR between the different subgroups, oth-
ers have noted increased rates of both local and regional 
recurrence to be significantly higher in TNBC and HER2 
subgroups compared with hormone receptor positive 
(HR) subtypes (Nguyen et  al. 2008; Voduc et  al. 2010; 
Gabos et al. 2010; Wang et al. 2011). Finally, the systemic 
meta-analysis have suggested a higher rate of local–
regional recurrence among TNBC subgroups compared 
with hormone receptor positive breast cancer either fol-
lowing BCT or mastectomy (Lowery et  al. 2012). Our 
series has a similar 13 % rate of local only recurrence. In 
addition, we also found a low rate of regional nodal fail-
ure of 4 %. While our report did not include other sub-
types and therefore cannot be compared among different 
subgroups, it nonetheless suggests a similar local failure 
rate compared with other reports. Report by Abdulkarim 
et al. (2011) and Gabos et al. (2010) suggested that TNBC 
had inferior local–regional recurrence following mastec-
tomy with/without radiation, but this was not confirmed 
by others.Thus, there is inadequate information to sug-
gest either BCT or mastectomy is a preferable mode of 
local treatment. Based on the current information, the 
decision regarding local–regional treatment should con-
sider disease stage, individual patient’s desire and type of 
systemic therapy and response.
The metastatic behavior of TNBC also is quite distinct 
compared with other subtypes. TNBC tends to metasta-
size more frequently to viscera compared with hormone 
receptor positive cancers. TNBC has been reported to 
have lung metastasis as the most frequent site compared 
with other sites (Anders and Carey 2009; Foulkes et  al. 
2010; Yagata et  al. 2011; Kennecke et  al. 2010). It also 
involves brain/CNS at a relative higher rate and lower rate 
of bone involvement (Anders and Carey 2009; Foulkes 
et al. 2010; Yagata et al. 2011; Kennecke et al. 2010) com-
pared with hormone receptor (HR) positive subtypes. 
Kennecke et al. (2010) reported cumulative incidence of 
lung metastasis for basal subtype to be 18.5  % followed 
by 16.6 % of bone, 10.9 % brain, 9.3 % liver and 17.2 % dis-
tant nodal failure. Similarly, our report showed the lungs 
to be the most distant failure site. In addition, we also 
noted higher incidence of non-regional nodal recurrence. 
Furthermore, brain, liver and bone involvement were 
common and in the similar range in our cohort. We did 
not see a higher rate of brain/CNS metastasis compared 
Fig. 2 The 2-, 5-, and 8-year overall (OS), disease-free (DFS), local 
failure-free (LFFS), and distant failure-free (DFFS) survival probabilities
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with bone involvement as documented in other studies. 
Since, most of the studies reported relative incidence dif-
ference; it is difficult to conclude whether this truly is the 
case. However, our rate of bone metastasis is similar to 
the report by Kennecke et al. (2010).
Significant racial disparity is well-known to exist for 
TNBC incidence. In particularly, black women have a 
higher likelihood of developing breast cancer with a 
triple negative phenotype and tend to be younger at 
diagnosis (Bowen et al. 2008; Huo et al. 2009). Socioeco-
nomics, cultural factors, and lack of adequate screening 
are believe to be important explanatory factors for this 
disparity. The issue of race and survival for women with 
TNBC specific subtypes has conflicting reports. Studies 
conducted by Bauer et al. (2007b) and Lund et al. (2009) 
found that black women have a worse survival for TNBC, 
after controlling for socioeconomic factors, treatment 
delay and tumor characteristics. Dawood et al. (2009) on 
the other hand found that the black race was not associ-
ated with a detriment in survival or likelihood of attain-
ing a pathological complete remission among patients 
with TNBC.
Our cohort of TNBC patients is unique in that there 
is an almost equal representation of black and white 
women, with a large sample size for each race. We found 
that among TNBC patients, there was no statistical dif-
ference in all 4 survival measures between black and 
white women. This is interesting, given that in our study 
white patients were more likely to have Stage IV disease 
and blacks were more likely to undergo BCS and RT. We 
also did not find any significant difference in pattern of 
failure between the two races. Future study is needed to 
determine if our findings reflect a unique regional varia-
tion for TNBC (DeSantis et al. 2016).
Our study has several limitations including its 
observational design and paucity of information on 
Fig. 3 a, b Overal (OS) and disease-free (DFS) survival by race. Adjusted hazard ratios (aHR) and 95 % confidence intervals (CI) are displayed in the 
lower left-hand corner of the graph
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post-surgery radiation dose and field employment. 
Information on neighborhood socioeconomic status, 
racial residential segregation, education level, and uti-
lization/access to long term follow-up care also was 
not available for our analysis. Furthermore, the adjust-
ment variables used in our multivariable model may 
have been incomplete (e.g., differences in tumor sever-
ity even within the categories we used for adjustment). 
However, our study is a large dataset including only 
triple negative subtype, with an equal representation of 
black race. This uniquely allowed us to show significant 
differences in demography and treatment but no differ-
ences in OS, DFS, LFFS, or DFFS. The lack of targeted 
hormonal therapy for TNBC coupled with the aggres-
sive nature of this tumor type may supersede the influ-
ence of race. Nonetheless, the factors affecting failure 
patterns and survival outcomes have a complex rela-
tionship and future research is needed to better under-
stand our results.
Conclusion
This is a large TNBC data set showing demographic 
treatment comparisons between black and white patients 
with no difference in failure patterns and survival out-
comes. For both races, distant failure was the predomi-
nant pattern of failure with lung being the most common 
site. Non-regional distant nodal failure was higher com-
pared with regional nodal failure.
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